A clinical-stage biopharmaceutical company advancing a pipeline of novel therapies for serious diseases with zero current revenue but significant cash burn funded by financing activities.
ADIL offers exposure to high-potential novel drug candidates at an early stage where the company has secured substantial funding ($95.2M paid-in capital) and maintained a healthy balance sheet with $5.9M in cash equivalents against only $1.4M in current liabilities. Investors may view the reduced losses from 2023 to 2024 as a sign of efficient resource allocation towards high-value assets before the next major clinical milestones.
The stock carries extreme risk due to zero revenue and gross profit, with a massive retained earnings deficit of $90.0M that must be offset by future successes or new capital raises. The company's inability to generate positive cash flow from operations ($-6.5M) and its reliance on financing activities for survival suggest that without a successful partnership deal or breakthrough trial, liquidity could become critical.
ADIAL Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat serious diseases, primarily operating in the United States with a pipeline centered on oncology and inflammation. The company leverages an asset-light model utilizing paid-in capital and financing activities to fund research and development while maintaining minimal current liabilities. With zero revenue from product sales recorded in the latest annual data, the firm relies entirely on successful clinical trials and future partnerships to generate commercial value.
The company reported a net loss of $8.0M in 2024, representing an improvement from the $13.2M loss in 2023, though still significantly higher than the $5.1M loss in 2023, indicating continued high R&D intensity with operating expenses totaling $7.8M. Despite a net change in cash of $2.1M driven by $8.5M in financing cash flows and share issuances of $3.7M, the negative operating cash flow highlights the capital-intensive nature of advancing its clinical pipeline without commercial sales.
The clinical-stage biopharmaceutical sector is characterized by high volatility where value is derived from pipeline assets rather than sales, requiring continuous capital infusion to navigate regulatory hurdles and clinical trial attrition. Companies in this space often operate with low current assets relative to liabilities until commercialization occurs, making cash flow management the primary determinant of survival.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $13.3M | $6.9M | $8.3M | $7.8M |
| Operating Income | $-13.3M | $-6.9M | $-8.3M | $-7.8M |
| R&D | $4.2M | $1.3M | $3.2M | $2.6M |
| G&A | $9.1M | $5.6M | $5.1M | $5.2M |
| Stock-Based Comp | $3.4M | $1.7M | $796.8K | $676.2K |
| Amortization | $564 | — | $565 | $565 |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $585.2K | $-113.9K | $-4.9M | $-177.7K |
| Interest Income | $63.2K | $69.8K | $178.7K | $149.6K |
| Pre-Tax Income | $-12.7M | $-7.0M | $-13.2M | $-8.0M |
| Income Tax | $-502 | $0 | $0 | $0 |
| Continuing Ops | $-12.7M | $-7.0M | $-13.2M | $-8.0M |
| Discontinued Ops | $0 | $1.9M | $0 | $0 |
| Net Income | $-12.7M | $-5.1M | $-13.2M | $-8.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-12.7M | $-5.1M | $-13.2M | $-8.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $4.8M | $3.2M | $4.1M | $6.2M |
| Cash & Equivalents | $4.0M | $2.8M | $3.8M | $5.9M |
| Prepaid Expenses | $349.4K | $371.6K | $308.2K | $299.7K |
| Other Current Assets | $428.7K | $0 | $0 | $0 |
| Long-Term Assets | $952.9K | $1.5M | $985.2K | $492.5K |
| PP&E (Net) | $50.4K | — | — | — |
| Intangibles | — | — | $3.3K | $2.8K |
| Goodwill | $249.0K | — | — | — |
| Operating Leases | $194.0K | — | — | — |
| Other LT Assets | $459.5K | $3.9K | $0 | $0 |
| Total Assets | $5.7M | $4.7M | $5.0M | $6.7M |
| Current Liabilities | $1.8M | $653.1K | $975.9K | $1.4M |
| Accounts Payable | $393.8K | $103.3K | $250.1K | $655.2K |
| Other Current Liab | $242.2K | $72.0K | $48.3K | $0 |
| Long-Term Liabilities | $665.4K | $0 | $0 | $0 |
| LT Operating Leases | $150.5K | — | — | — |
| Other LT Liab | $514.9K | — | — | — |
| Total Liabilities | $2.5M | $653.1K | $975.9K | $1.4M |
| Shareholders' Equity | $3.3M | $4.1M | $4.1M | $5.3M |
| Paid-In Capital | $66.9M | $72.9M | $86.1M | $95.2M |
| Retained Earnings | $-63.7M | $-68.8M | $-82.0M | $-90.0M |
| Total L&E | $5.7M | $4.7M | $5.0M | $6.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-12.7M | $-5.1M | $-13.2M | $-8.0M |
| Non-Cash Adjustments | $2.2M | $-1.1M | $6.0M | $939.5K |
| Working Capital Changes | $-609.6K | $-622.8K | $307.4K | $545.1K |
| Cash from Operations | $-11.2M | $-6.8M | $-6.9M | $-6.5M |
| Cash from Investing | $0 | $1.5M | $0 | $150.0K |
| Share Buybacks | — | $1.7K | — | — |
| Cash from Financing | $9.1M | $4.1M | $7.8M | $8.5M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-2.1M | $-1.2M | $923.4K | $2.1M |
| Beginning Cash | $6.1M | $4.0M | $2.8M | $3.8M |
| Ending Cash | $4.0M | $2.8M | $3.8M | $5.9M |
Oncology Therapeutics Development, Inflammation Disease Targets, and Research & Technology Platform utilizing proprietary discovery methods to advance candidate molecules into clinical trials.
Substantial net loss of $8.0M coupled with zero revenue creates high burn risk dependent on successful external financing or strategic partnerships, lack of commercial products means no current cash flow from operations at -$6.5M, and the inherent high failure rate of clinical-stage biotech assets without established market presence.
Significant paid-in capital base of $95.2M providing a robust runway for R&D operations, specialized expertise in novel target identification reducing the typical attrition rate of early-stage drug development, and a lean operational structure with low current liabilities relative to cash reserves.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.